Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

TACE: a new target in epidermal growth factor receptor dependent tumors.

Kenny PA.

Differentiation. 2007 Nov;75(9):800-8. Epub 2007 Jul 2. Review.

PMID:
17608729
2.

Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer.

Kenny PA.

Expert Opin Ther Targets. 2007 Oct;11(10):1287-98. Review.

PMID:
17907959
3.

Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency.

Hinkle CL, Sunnarborg SW, Loiselle D, Parker CE, Stevenson M, Russell WE, Lee DC.

J Biol Chem. 2004 Jun 4;279(23):24179-88. Epub 2004 Apr 5.

4.

ADAM proteases, ErbB pathways and cancer.

Zhou BB, Fridman JS, Liu X, Friedman SM, Newton RC, Scherle PA.

Expert Opin Investig Drugs. 2005 Jun;14(6):591-606. Review.

PMID:
16004590
5.

TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase.

Lee DC, Sunnarborg SW, Hinkle CL, Myers TJ, Stevenson MY, Russell WE, Castner BJ, Gerhart MJ, Paxton RJ, Black RA, Chang A, Jackson LF.

Ann N Y Acad Sci. 2003 May;995:22-38. Review.

PMID:
12814936
6.

Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability.

Sunnarborg SW, Hinkle CL, Stevenson M, Russell WE, Raska CS, Peschon JJ, Castner BJ, Gerhart MJ, Paxton RJ, Black RA, Lee DC.

J Biol Chem. 2002 Apr 12;277(15):12838-45. Epub 2002 Jan 31.

8.

EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.

Kataoka H.

J Dermatol Sci. 2009 Dec;56(3):148-53. doi: 10.1016/j.jdermsci.2009.10.002. Epub 2009 Nov 6. Review.

PMID:
19896805
9.

Multiple shRNA-mediated knockdown of TACE reduces the malignancy of HeLa cells.

Yan Y, Zhang J, Guo JL, Huang W, Yang YZ.

Cell Biol Int. 2009 Feb;33(2):158-64. doi: 10.1016/j.cellbi.2008.10.008. Epub 2008 Nov 1.

PMID:
18996214
10.

Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme.

Merlos-Suárez A, Ruiz-Paz S, Baselga J, Arribas J.

J Biol Chem. 2001 Dec 21;276(51):48510-7. Epub 2001 Oct 12.

12.
13.

TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion.

Giricz O, Calvo V, Peterson EA, Abouzeid CM, Kenny PA.

Int J Cancer. 2013 Dec 1;133(11):2587-95. doi: 10.1002/ijc.28295. Epub 2013 Jun 21.

14.

Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.

Zheng X, Jiang F, Katakowski M, Kalkanis SN, Hong X, Zhang X, Zhang ZG, Yang H, Chopp M.

Cancer Sci. 2007 May;98(5):674-84. Epub 2007 Mar 9.

15.

EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing.

Ruhe JE, Streit S, Hart S, Ullrich A.

Cell Signal. 2006 Sep;18(9):1515-27. Epub 2006 Feb 14.

PMID:
16478662
16.

Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors.

Santiago-Josefat B, Esselens C, Bech-Serra JJ, Arribas J.

J Biol Chem. 2007 Mar 16;282(11):8325-31. Epub 2007 Jan 16.

17.

Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma.

Ringel J, Jesnowski R, Moniaux N, Lüttges J, Ringel J, Choudhury A, Batra SK, Klöppel G, Löhr M.

Cancer Res. 2006 Sep 15;66(18):9045-53.

18.

Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17.

Sahin U, Blobel CP.

FEBS Lett. 2007 Jan 9;581(1):41-4. Epub 2006 Dec 6.

19.

Targeting ligand cleavage to inhibit the ErbB pathway in cancer.

Zhou BB.

Ann N Y Acad Sci. 2005 Nov;1059:56-60. Review.

PMID:
16382043
Items per page

Supplemental Content

Write to the Help Desk